Synthesis of Deuterium-Labeled Zaleplon-d₅

Introduction

Zaleplon is a pyrazolopyrimidine sedative-hypnotic agent licensed for the short-term treatment of insomnia. Due to its potential for abuse and addiction, zaleplon is classified as a controlled substance in some countries. Accurate analysis and identification of zaleplon in drug abuse cases requires the use of isotopically labeled internal standards, such as zaleplon-d₅.

Here, we present the synthesis of deuterium-labeled zaleplon-d₅, which can serve as an internal standard for the GC-MS analysis of zaleplon.

Product List

Click the product name to view product details.

CAS Number	Product Name	Inquiry
1001083-56-2	Zaleplon-d₅	Inquiry
1227694-96-3	Zaleplon Related Compound A	Inquiry
1781887-91-9	Zaleplon-D4 solution	Inquiry
478081-98-0	Zaleplon Related Compound B	Inquiry
940951-54-2	Zaleplon Related Compound C	Inquiry
1227694-78-1	Zaleplon Impurity 3	Inquiry
159225-99-7	Zaleplon Impurity 4	Inquiry
478081-98-0	Zaleplon Impurity 1	Inquiry
96605-66-2	Zaleplon Impurity 2	Inquiry

Synthesis of Zaleplon-d₅ by Scheme 1

Our first route to zaleplon-d₅ shown in Scheme 1.

Initially, 3nitroacetophenone 1 was treated with N,N-dimethylformamide dimethylacetal under reflux to yield the intermediate, enamide 2.
Another key intermediate, 5-amino-1H-pyrazole-4-carbonitrile (4) was obtained by refluxing ethoxymethylenemalononitrile (3) and hydrazine hydrate in ethanol.
In the following step, compounds 4 and 2 underwent cyclization under mild acidic condition at reflux to yield 7-(3-nitro-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile (5).
An efficient reduction of 5 using 10% Pd/C catalyst at an H pressure of 60 psi gave 7-(3-amino-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile (6).
The 3-amino phenyl pyrazolopyrimidine 6 was treated with an acetic anhydride and pyridine to produce acetamide 7.
Introduction of the isotopic label was attempted by treating acetamide 7 with ethyl iodide-din the presence of sodium hydride, under an inert atmosphere at 50℃.

Unfortunately, the yield of zaleplon-d₅ obtained was negligible. Various alternative conditions were tried, but the maximum yield obtained was only 20%. The purification of zaleplon-d₅ was also problematic, as zaleplon-d₅ could not be successfully crystallized and was difficult to elute from a silica gel column. Therefore, this route was abandoned.

Fig.1 Scheme 1 for the synthesis of zaleplon-d5

Synthesis of Zaleplon-d₅ by Scheme 2

The synthesis started from compound 1, which is readily available and inexpensive. 3'-Nitroacetophenone 1 was reduced to 3'-aminoacetophenone 9.
Subsequently, Acylation to generate acetamide 10, which in turn was treated with N,N-dimethylformamide dimethylacetal to produce enamide 11.
Enamide 11 was alkylated using ethyl iodide-d₅ and sodium hydride as base at room temperature to yield the N-ethylated enamide 12.
In the final step, N-ethylenamide 12 was coupled with 5-aminopyrazole 4 in aqueous acid at 50℃ to produce zaleplon-d₅ 8 in 85% yield.
Further purification by recrystallization of the crude product from 30% aqueous acetic acid yielded colorless crystals of zaleplon-d₅ 8.

Fig.2 Scheme 2 for the synthesis of zaleplon-d5

In conclusion, this work provides an elegant route to zaleplon-d₅, an internal standard for zaleplon analysis. This synthesis paves the way for the quantitative detection of zaleplon in drug abusers.

Reference

Shaikh, A. C., & Chen, C. Synthesis of deuterium-labeled zaleplon-d₅ as an internal standard. Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal of the International Isotope Society. 2008, 51(1), 72-76.

Resources

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.

Online Inquiry

Synthesis of Deuterium-Labeled Zaleplon-d5

Introduction

Synthesis of Zaleplon-d5 by Scheme 1

Synthesis of Zaleplon-d5 by Scheme 2

Reference

Synthesis of Deuterium-Labeled Zaleplon-d₅

Synthesis of Zaleplon-d₅ by Scheme 1

Synthesis of Zaleplon-d₅ by Scheme 2